|
Gene: ENDOV |
Gene summary for ENDOV |
Gene summary. |
Gene information | Species | Human | Gene symbol | ENDOV | Gene ID | 284131 |
Gene name | endonuclease V | |
Gene Alias | ENDOV | |
Cytomap | 17q25.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N8Q3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284131 | ENDOV | LZE4T | Human | Esophagus | ESCC | 8.22e-08 | 2.61e-01 | 0.0811 |
284131 | ENDOV | LZE7T | Human | Esophagus | ESCC | 2.92e-03 | 2.03e-01 | 0.0667 |
284131 | ENDOV | LZE8T | Human | Esophagus | ESCC | 1.77e-03 | 1.28e-01 | 0.067 |
284131 | ENDOV | LZE22T | Human | Esophagus | ESCC | 2.35e-06 | 4.62e-01 | 0.068 |
284131 | ENDOV | LZE24T | Human | Esophagus | ESCC | 1.29e-16 | 4.33e-01 | 0.0596 |
284131 | ENDOV | LZE6T | Human | Esophagus | ESCC | 7.26e-03 | 2.53e-01 | 0.0845 |
284131 | ENDOV | P1T-E | Human | Esophagus | ESCC | 2.73e-05 | 2.49e-01 | 0.0875 |
284131 | ENDOV | P2T-E | Human | Esophagus | ESCC | 1.64e-16 | 2.71e-01 | 0.1177 |
284131 | ENDOV | P4T-E | Human | Esophagus | ESCC | 2.03e-07 | 1.68e-01 | 0.1323 |
284131 | ENDOV | P5T-E | Human | Esophagus | ESCC | 9.45e-10 | 2.30e-01 | 0.1327 |
284131 | ENDOV | P8T-E | Human | Esophagus | ESCC | 6.06e-26 | 4.52e-01 | 0.0889 |
284131 | ENDOV | P9T-E | Human | Esophagus | ESCC | 5.15e-11 | 2.43e-01 | 0.1131 |
284131 | ENDOV | P10T-E | Human | Esophagus | ESCC | 1.38e-16 | 3.30e-01 | 0.116 |
284131 | ENDOV | P11T-E | Human | Esophagus | ESCC | 5.85e-19 | 8.18e-01 | 0.1426 |
284131 | ENDOV | P12T-E | Human | Esophagus | ESCC | 4.21e-16 | 2.21e-01 | 0.1122 |
284131 | ENDOV | P15T-E | Human | Esophagus | ESCC | 1.16e-18 | 4.20e-01 | 0.1149 |
284131 | ENDOV | P16T-E | Human | Esophagus | ESCC | 1.19e-12 | 1.89e-01 | 0.1153 |
284131 | ENDOV | P17T-E | Human | Esophagus | ESCC | 1.58e-05 | 2.86e-01 | 0.1278 |
284131 | ENDOV | P19T-E | Human | Esophagus | ESCC | 1.72e-02 | 2.22e-01 | 0.1662 |
284131 | ENDOV | P20T-E | Human | Esophagus | ESCC | 5.04e-41 | 9.54e-01 | 0.1124 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:00905023 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
GO:00905012 | Oral cavity | OSCC | RNA phosphodiester bond hydrolysis | 95/7305 | 152/18723 | 3.65e-09 | 8.22e-08 | 95 |
GO:00903052 | Oral cavity | OSCC | nucleic acid phosphodiester bond hydrolysis | 142/7305 | 261/18723 | 2.90e-07 | 4.43e-06 | 142 |
GO:00905022 | Oral cavity | OSCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 44/7305 | 82/18723 | 4.95e-03 | 1.94e-02 | 44 |
GO:00905015 | Thyroid | PTC | RNA phosphodiester bond hydrolysis | 76/5968 | 152/18723 | 2.40e-06 | 3.17e-05 | 76 |
GO:00903055 | Thyroid | PTC | nucleic acid phosphodiester bond hydrolysis | 105/5968 | 261/18723 | 2.53e-03 | 1.31e-02 | 105 |
GO:009050112 | Thyroid | ATC | RNA phosphodiester bond hydrolysis | 76/6293 | 152/18723 | 2.07e-05 | 1.86e-04 | 76 |
GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENDOV | SNV | Missense_Mutation | c.454N>C | p.Gly152Arg | p.G152R | Q8N8Q3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ENDOV | SNV | Missense_Mutation | novel | c.100N>A | p.Glu34Lys | p.E34K | Q8N8Q3 | protein_coding | tolerated(0.26) | benign(0.232) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ENDOV | SNV | Missense_Mutation | rs775146831 | c.665N>A | p.Arg222His | p.R222H | Q8N8Q3 | protein_coding | deleterious(0.04) | benign(0.038) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ENDOV | SNV | Missense_Mutation | novel | c.31N>C | p.Glu11Gln | p.E11Q | Q8N8Q3 | protein_coding | deleterious(0.04) | benign(0.118) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ENDOV | SNV | Missense_Mutation | c.13N>A | p.Ala5Thr | p.A5T | Q8N8Q3 | protein_coding | tolerated(0.09) | benign(0.444) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ENDOV | SNV | Missense_Mutation | novel | c.455N>A | p.Gly152Glu | p.G152E | Q8N8Q3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ENDOV | SNV | Missense_Mutation | c.286N>A | p.Leu96Met | p.L96M | Q8N8Q3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ENDOV | SNV | Missense_Mutation | c.659C>T | p.Ala220Val | p.A220V | Q8N8Q3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ENDOV | SNV | Missense_Mutation | novel | c.17N>T | p.Ala6Val | p.A6V | Q8N8Q3 | protein_coding | tolerated(0.42) | benign(0.028) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ENDOV | SNV | Missense_Mutation | rs747412732 | c.785N>T | p.Pro262Leu | p.P262L | Q8N8Q3 | protein_coding | tolerated_low_confidence(0.37) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |